876 related articles for article (PubMed ID: 23470275)
1. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.
O' Neill C
Exp Gerontol; 2013 Jul; 48(7):647-53. PubMed ID: 23470275
[TBL] [Abstract][Full Text] [Related]
2. Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease.
O'Neill C; Kiely AP; Coakley MF; Manning S; Long-Smith CM
Biochem Soc Trans; 2012 Aug; 40(4):721-7. PubMed ID: 22817723
[TBL] [Abstract][Full Text] [Related]
3. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells.
Shrivastava S; Kulkarni P; Thummuri D; Jeengar MK; Naidu VG; Alvala M; Redddy GB; Ramakrishna S
Apoptosis; 2014 Jul; 19(7):1148-64. PubMed ID: 24729100
[TBL] [Abstract][Full Text] [Related]
4. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
5. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
[TBL] [Abstract][Full Text] [Related]
6. Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease.
Castri P; Iacovelli L; De Blasi A; Giubilei F; Moretti A; Tari Capone F; Nicoletti F; Orzi F
Eur J Neurosci; 2007 Nov; 26(9):2469-72. PubMed ID: 17986027
[TBL] [Abstract][Full Text] [Related]
7. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
Tramutola A; Triplett JC; Di Domenico F; Niedowicz DM; Murphy MP; Coccia R; Perluigi M; Butterfield DA
J Neurochem; 2015 Jun; 133(5):739-49. PubMed ID: 25645581
[TBL] [Abstract][Full Text] [Related]
8. Phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target?
Huang T; Lin X; Meng X; Lin M
Acta Derm Venereol; 2014 Jul; 94(4):371-9. PubMed ID: 24217655
[TBL] [Abstract][Full Text] [Related]
9. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
[TBL] [Abstract][Full Text] [Related]
10. The phosphatidylinositol 3' kinase-Akt-mammalian target of rapamycin pathway in smooth muscle tumors of the uterus: selected protein expression patterns and their clinicopathologic implications.
Fadare O; Renshaw I; Olson SJ; Liang SX
Int J Gynecol Pathol; 2011 May; 30(3):244-51. PubMed ID: 21464729
[TBL] [Abstract][Full Text] [Related]
11. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
12. The PI3K/AKT Pathway as a Target for Cancer Treatment.
Mayer IA; Arteaga CL
Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
14. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
[TBL] [Abstract][Full Text] [Related]
15. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
16. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
17. Targeting PI3 kinase in cancer.
Bauer TM; Patel MR; Infante JR
Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
[TBL] [Abstract][Full Text] [Related]
18. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease.
Ho L; Qin W; Pompl PN; Xiang Z; Wang J; Zhao Z; Peng Y; Cambareri G; Rocher A; Mobbs CV; Hof PR; Pasinetti GM
FASEB J; 2004 May; 18(7):902-4. PubMed ID: 15033922
[TBL] [Abstract][Full Text] [Related]
19. mTOR and autophagy in normal brain aging and caloric restriction ameliorating age-related cognition deficits.
Yang F; Chu X; Yin M; Liu X; Yuan H; Niu Y; Fu L
Behav Brain Res; 2014 May; 264():82-90. PubMed ID: 24525424
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
